Dysregulation of DNA damage repair and signalling to cell cycle checkpoints, known as the
DNA damage response (DDR), is associated with a predisposition to cancer and affects …

Many patients with malignant gliomas do not respond to alkylating agent chemotherapy.
Alkylator resistance of glioma cells is mainly mediated by the DNA repair enzyme O 6 …

Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care
for newly diagnosed glioblastoma (GBM). O6-methylguanine-DNA methyltransferase …

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are heterogeneous
regarding site of origin, biological behavior, and malignant potential. There has been a rapid …

Tumor recurrence following treatment is the major cause of mortality for glioblastoma
multiforme (GBM) patients. Thus, insights on the evolutionary process at recurrence are …

Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine
bases of DNA (O6-guanine; N7-guanine and N3-adenine), is frequently used together with …

Glioblastoma multiforme (GBM) or astrocytoma grade Ⅳ on WHO classification is the most
aggressive and the most frequent of all primary brain tumors. Glioblastoma is multiforme …

The breast cancer stem cell (BCSC) hypotheses suggest that breast cancer is derived from a
single tumor-initiating cell with stem-like properties, but the source of these cells is unclear …

Intrinsic or acquired chemoresistance to alkylating agents is a major cause of treatment
failure in patients with malignant brain tumors. Alkylating agents, the mainstay of treatment …

Purpose: Recent studies suggest that temozolomide has activity in neuroendocrine tumors.
Low levels of the DNA repair enzyme, O 6-methylguanine DNA methyltransferase (MGMT) …